Tailoring patients’ enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs
暂无分享,去创建一个
A. Chiò | G. Mora | A. Calvo | C. Moglia | M. C. Torrieri | U. Manera | A. Canosa | R. Vasta | G. Fuda | P. Salamone | M. Grassano | P. Cugnasco | N. Launaro | F. De Marchi | A. Mattei | L. Mazzini
[1] O. Witte,et al. Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19 Pandemic: An Application of the D50 Model , 2020, Journal of clinical medicine.
[2] L. H. van den Berg,et al. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis , 2020, Current opinion in neurology.
[3] A. Chiò,et al. Prognostic role of slow vital capacity in amyotrophic lateral sclerosis , 2020, Journal of Neurology.
[4] A. Chiò,et al. Disease-modifying therapies in amyotrophic lateral sclerosis , 2020, Neuropharmacology.
[5] C. Mcdermott. Clinical trials in amyotrophic lateral sclerosis. , 2019, Current opinion in neurology.
[6] A. Chiò,et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[7] A. Chiò,et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials , 2019, Neurology.
[8] M. Jaiswal,et al. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs , 2018, Medicinal research reviews.
[9] Annelot M. Dekker,et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model , 2018, The Lancet Neurology.
[10] Laurel Richardson,et al. The Writing Group , 2018 .
[11] Albert A. Taylor,et al. Improved stratification of ALS clinical trials using predicted survival , 2018, Annals of clinical and translational neurology.
[12] Y. Itoyama,et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.
[13] H. Mitsumoto,et al. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? , 2014, The Lancet Neurology.
[14] N. Nishimoto,et al. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. , 2013, American journal of neurodegenerative disease.
[15] K. Schulz,et al. Sample size calculations in randomised trials: mandatory and mystical , 2005, The Lancet.
[16] A. Al-Chalabi,et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.
[17] M. Swash,et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[18] L. Kux. OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .
[19] E. Beghi,et al. Modeling drop-outs in amyotrophic lateral sclerosis. , 2012, Contemporary clinical trials.